According to the company, this newly planned Phase II trial is tentatively scheduled to start mid-2008 and will involve up to 500 participants at several locations in the US.
Harriet Robinson, senior vice president, R&D at GeoVax, said: “Our vaccine continues to demonstrate the promise of not only being safe but also effective at eliciting potentially protective immune responses.”